Michael Kauffman
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael Kauffman
Michael Kauffman was last confirmed as CEO at Karyopharm Therapeutics Inc. (KPTI) in a filing dated April 8, 2022. Earlier roles on record: Board Member at Karyopharm Therapeutics Inc. (KPTI) until March 22, 2022. The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $3,069,589 for Michael Kauffman in fiscal 2021, including a base salary of $474,375. Disclosed compensation is on record for 4 fiscal years. Michael Kauffman has spoken on 5 earnings calls across 1 company, most recently for Karyopharm Therapeutics Inc. on May 3, 2021.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2022-04-08
Last confirmed by a filing; no departure on record
-
Start not stated–2022-03-22
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Karyopharm Therapeutics Inc. (KPTI) | M.D., Ph.D. | $474,375 | $3,069,589 |
| 2020 | Karyopharm Therapeutics Inc. (KPTI) | M.D., Ph.D. Chief Executive Officer | $625,624 | $3,937,039 |
| 2019 | Karyopharm Therapeutics Inc. (KPTI) | M.D., Ph.D. Chief Executive Officer | $566,500 | $3,231,504 |
| 2018 | Karyopharm Therapeutics Inc. (KPTI) | M.D., Ph.D. Chief Executive Officer | $550,000 | $2,274,945 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.